Health Care • Biotechnology: Pharmaceutical Preparations
$3.04 ▼ -0.14
(-4.40%)
MKT CAP: $228.5M • VOL: 504.7K
52W L $3 52W H $8
SIGA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $94.6M | $138.7M | $139.9M |
| YoY Revenue Growth % | -31.8% | -0.9% | — |
| Gross Profit | $64.9M | $107.4M | — |
| Gross Margin % | 68.6% | 77.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $23.7M | $70.0M | $83.6M |
| Operating Margin % | 25.1% | 50.4% | 59.8% |
| Net Income (GAAP) | $23.3M | $59.2M | $68.1M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $43.5M | $48.8M | $94.8M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $43.5M | $48.8M | $94.8M |
| FCF Margin % | 46.0% | 35.2% | 67.8% |
| Return on Invested Capital (ROIC %) | 42.7% | 91.5% | — |
| Cash & Short-Term Equivalents | $155.0M | $155.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $198.8M | $215.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SIGA.